Video: Marty Tenenbaum Speaks at Microsoft Research

Cancer Commons founder Marty Tenenbaum, PhD, recently visited Microsoft’s Richmond, CA, office to give a presentation entitled “How to Beat Cancer.”

Because of “a convergence of recent developments in genomics, big data informatics, social networks, and personalized medicine that is transforming the landscape of cancer research and treatment,” Marty says, “we are now on the threshold of being able to give each individual the knowledge, resources, and tools needed to successfully treat the one disease that matters most to them.”

Watch the complete presentation at the Microsoft Research site.


Marty Tenenbaum to Lead Panel Discussion at 2014 Personalized Medicine World Conference

Cancer Commons founder Marty Tenenbaum will lead a panel discussion at the 2014 Personalized Medicine World Conference (PMWC) on Jan 27. The discussion, entitled, “PM in Oncology Today: Making It Work for Patients, Clinicians, Researchers, and Industry,” will also feature George Demetri of Dana-Farber/Harvard Cancer Center, Vincent A. Miller of Foundation Medicine, lung cancer survivor Neil Schiffman, and Edgar Staren of CTCA Medicine and Science. Their diverse perspectives will ignite insightful discussion regarding the current use and future promise of personalized medicine in cancer.

The 6th annual PMWC conference in Silicon Valley runs Jan 27–28. It brings together leaders from multiple sectors—including business, government, healthcare-delivery, research and technology—to learn from each other and further the field of personalized medicine. Dr. Tenenbaum’s panel discussion is at 11 am on the main-stage. General registration is available through Jan 24.


Marty Tenenbaum to Speak at Monte Jade Forum on Personalized Medicine

Cancer Commons founder Marty Tenenbaum, PhD, will speak tomorrow at the Monte Jade Forum, an event organized by the Monte Jade Science and Technology Association (West Coast). The Forum is entitled Personalized Precision Medicine – What does it mean for the cancer patient? Dr. Tenenbaum will join oncologist Edmund Tai, MD, in a discussion of how personalized medicine, or “precision oncology,” can help cancer patients. Dr. Tenenbaum will discuss Cancer Commons as “an emerging patient-led movement that empowers each patient and their care team to get the best available knowledge for beating their cancer, and to update that knowledge in real time based on each patient’s outcome.”

The Forum takes place tomorrow, Nov 6, 2013, at 7:00pm at ITRI International in San Jose, CA. Registration is available online, and non-members can register for $20.


"How to Beat Cancer:" Marty Tenenbaum to Speak at Silicom Ventures' Monthly Meeting

Cancer Commons founder Dr. Marty Tenenbaum will be speaking tomorrow at the monthly meeting of Silicom Ventures, a Silicon Valley-based investment forum. Dr. Tenenbaum will discuss his vision for a personalized approach to oncology, offering solutions that could help answer these questions:

-Which are the best drugs and trials for me?
-How can I get timely and affordable access to the latest investigational drugs?
-How can we slash the time and cost of drug development so that the economics work for therapies that target small subsets of patients?
-Can cancer research be funded, one patient at a time?

The meeting takes place tomorrow, Sep. 10, in Santa Clara, CA. Guest registration is available on the event page.


Two More Days to Ask Anything About Lung Cancer for CancerConnect Event

From June 26 to 27, lung cancer expert David M. Jackman, MD, will answer patient-submitted questions as a moderator on the social media cancer website CancerConnect. Dr. Jackman is a thoracic oncologist at Dana-Farber Cancer Institute in Boston. According to CancerConnect, “his research interests include evaluating how to predict responses to targeted therapy in non-small cell lung cancer (NSCLC).” Questions can be submitted here.


Upcoming Event: Ask Anything About Lung Cancer

From June 26-27, lung cancer expert David M. Jackman, MD, will answer patient-submitted questions as a moderator on the social media cancer website CancerConnect. Dr. Jackman is a thoracic oncologist at Dana-Farber Cancer Institute. According to CancerConnect, “his research interests include evaluating how to predict responses to targeted therapy in non-small cell lung cancer (NSCLC).” Questions can be submitted here.


Upcoming Event: Ask Anything About Lung Cancer

From June 26 to 27, lung cancer expert David M. Jackman, MD, will answer patient-submitted questions as a moderator on the social media cancer Web site CancerConnect. Dr. Jackman is a thoracic oncologist at Dana-Farber Cancer Institute in Boston. According to CancerConnect, “his research interests include evaluating how to predict responses to targeted therapy in non-small cell lung cancer (NSCLC).” Questions can be submitted here.


Dr. Tenenbaum to Speak as Panel Host for The Scientist Magazine's Webinar Series

On Tuesday, May 7, Dr. Tenenbaum will host a panel in The Scientists three-part webinar series Decoding DNA: New Twists and Turns. The series, which began on April 18, takes “a bold look at what the future holds for DNA research, bringing together senior investigators and key leaders in the field of genetics and genomics.” Dr. Tenenbaum will speak during the final webinar, The Impact of Personalized Medicine.

From The Scientist‘s description:

“After the human genome was sequenced, Personalized Medicine became an end goal, driving both academia and the pharma/biotech industry to find and target cellular pathways and drug therapies that are unique to an individual patient. The final webinar in the series will help us better understand The Impact of Personalized Medicine, what we can expect to gain and where we stand to lose.”

Dr. Tenenbaum will be joined by Amy P. Abernethy, M.D., Associate Professor of Medicine, Duke University School of Medicine and Director of the Duke Cancer Care Research Program; and Abhijit “Ron” Mazumder, Ph.D., Global Head, Research & Product Development, Janssen Diagnostics, Janssen Pharmaceutical companies of Johnson and Johnson.

When: Tuesday, May 7, 2013, 2:30–4:00 pm ET. Register here.